Zviadi Aburjania1, Samuel Jang1, Celina Montemayor-Garcia2, Ricardo V Lloyd2, David F Schneider3, Rebecca S Sippel3, Herbert Chen4, Dawn M Elfenbein5. 1. Department of Surgery, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama. 2. Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 3. Department of Surgery, UW Hospital and Clinics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 4. Department of Surgery, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama. Electronic address: herbchen@uab.edu. 5. Department of Surgery, University of California, Irvine, California.
Abstract
BACKGROUND: Recent studies suggest that the encapsulated form of follicular variant of papillary thyroid cancer (eFVPTC) behaves more similarly to benign lesions and can be treated with thyroid lobectomy alone instead of total thyroidectomy. To distinguish aggressive cancers from more benign lesions more clearly, the objective of this study was to determine if the eFVPTC behaves less aggressively than the nonencapsulated variant (neFVPTC). METHODS: A prospectively collected endocrine surgery database in our institution was reviewed for all patients with FVPTC on surgical pathology from 1999 to 2012. Samples were rereviewed to determine if the tumor was eFVPTC or neFVPTC, which were correlated with patient outcomes. RESULTS: Of the 68 patients, 59 (87%) had eFVPTC and 9 (13%) had neFVPTC. The mean age was 48 y and 63% were female. Fifty-four of 64 patients (84%) who had a total thyroidectomy received radioactive iodine. The eFVPTC group had lower rates of cervical LN involvement (5% versus 22%, P = 0.2504). The median follow-up time was 3 y (0-13 y) and only two patients had recurrence, one with eFVPTC and one with neFVPTC. None of the patients had distant metastasis or died of their disease. CONCLUSIONS: eFVPTCs appear to have a lower rate of cervical lymph node metastases compared with neFVPTCs, but recurrent disease may be seen in both subtypes. These findings suggest eFVPTC can be managed more conservatively.
BACKGROUND: Recent studies suggest that the encapsulated form of follicular variant of papillary thyroid cancer (eFVPTC) behaves more similarly to benign lesions and can be treated with thyroid lobectomy alone instead of total thyroidectomy. To distinguish aggressive cancers from more benign lesions more clearly, the objective of this study was to determine if the eFVPTC behaves less aggressively than the nonencapsulated variant (neFVPTC). METHODS: A prospectively collected endocrine surgery database in our institution was reviewed for all patients with FVPTC on surgical pathology from 1999 to 2012. Samples were rereviewed to determine if the tumor was eFVPTC or neFVPTC, which were correlated with patient outcomes. RESULTS: Of the 68 patients, 59 (87%) had eFVPTC and 9 (13%) had neFVPTC. The mean age was 48 y and 63% were female. Fifty-four of 64 patients (84%) who had a total thyroidectomy received radioactive iodine. The eFVPTC group had lower rates of cervical LN involvement (5% versus 22%, P = 0.2504). The median follow-up time was 3 y (0-13 y) and only two patients had recurrence, one with eFVPTC and one with neFVPTC. None of the patients had distant metastasis or died of their disease. CONCLUSIONS: eFVPTCs appear to have a lower rate of cervical lymph node metastases compared with neFVPTCs, but recurrent disease may be seen in both subtypes. These findings suggest eFVPTC can be managed more conservatively.
Authors: Michael Rivera; Julio Ricarte-Filho; Jeff Knauf; Ashok Shaha; Michael Tuttle; James A Fagin; Ronald A Ghossein Journal: Mod Pathol Date: 2010-06-04 Impact factor: 7.842
Authors: Yuri E Nikiforov; Raja R Seethala; Giovanni Tallini; Zubair W Baloch; Fulvio Basolo; Lester D R Thompson; Justine A Barletta; Bruce M Wenig; Abir Al Ghuzlan; Kennichi Kakudo; Thomas J Giordano; Venancio A Alves; Elham Khanafshar; Sylvia L Asa; Adel K El-Naggar; William E Gooding; Steven P Hodak; Ricardo V Lloyd; Guy Maytal; Ozgur Mete; Marina N Nikiforova; Vania Nosé; Mauro Papotti; David N Poller; Peter M Sadow; Arthur S Tischler; R Michael Tuttle; Kathryn B Wall; Virginia A LiVolsi; Gregory W Randolph; Ronald A Ghossein Journal: JAMA Oncol Date: 2016-08-01 Impact factor: 31.777
Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky Journal: Thyroid Date: 2016-01 Impact factor: 6.568
Authors: Jeffrey Liu; Bhuvanesh Singh; Giovanni Tallini; Diane L Carlson; Nora Katabi; Ashok Shaha; R Michael Tuttle; Ronald A Ghossein Journal: Cancer Date: 2006-09-15 Impact factor: 6.860
Authors: Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Andrew K Stewart; David P Winchester; Mark S Talamonti; Cord Sturgeon Journal: Ann Surg Date: 2007-09 Impact factor: 12.969
Authors: David N Parente; Pim J Bongers; Raoul Verzijl; Lorne E Rotstein; Sylvia L Asa; Wouter P Kluijfhout; Karen M Devon; David P Goldstein; Ozgur Mete; Jesse D Pasternak Journal: World J Surg Date: 2018-07 Impact factor: 3.352
Authors: Juan C Hernandez-Prera; Pablo Valderrabano; Jordan H Creed; Janis V de la Iglesia; Robbert J C Slebos; Barbara A Centeno; Valentina Tarasova; Julie Hallanger-Johnson; Colleen Veloski; Kristen J Otto; Bruce M Wenig; Sean J Yoder; Cesar A Lam; Derek S Park; Alexander R Anderson; Natarajan Raghunand; Anders Berglund; Jimmy Caudell; Travis A Gerke; Christine H Chung Journal: Thyroid Date: 2020-08-25 Impact factor: 6.568